e-Therapeutics (ETX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

11.00p
   
  • Change Today:
    -0.15p
  • 52 Week High: 23.10
  • 52 Week Low: 8.13
  • Currency: UK Pounds
  • Shares Issued: 584.34m
  • Volume: 169,640
  • Market Cap: £64.28m

E-therapeutics enters collaboration deal with Galapagos

By Josh White

Date: Wednesday 10 Jun 2020

LONDON (ShareCast) - (Sharecast News) - E-therapeutics has entered a collaboration agreement with Galapagos to identify new therapeutic approaches to modulate a specific mechanism involved in idiopathic pulmonary fibrosis (IPF), and potentially in other fibrotic indications, it announced on Wednesday.
The AIM-traded firm said it would still be free to explore, both internally and with additional partners, all other pathways involved in IPF and fibrosis.

It said the collaboration would combine its expertise in network biology and in silico phenotypic screening, with Galapagos' knowledge of IPF and fibrosis.

E-therapeutics said it would apply its proprietary 'network-driven drug discovery' (NDD) platform and know-how to identify new strategies to modulate a specific pathway of interest to Galapagos, selecting potentially clinically relevant compounds for the treatment of IPF and fibrosis.

As part of the collaboration, e-therapeutics said it would be responsible for all computational activities, and Galapagos will perform all experimental testing.

Under the terms of the agreement, e-therapeutics would receive upfront and near-term payments material to its cash position, and would also be eligible to receive preclinical and clinical development and commercial milestone payments.

"We look forward to working with Galapagos on this project in areas of clear unmet medical need such as IPF and fibrosis," said executive chairman Ali Mortazavi.

"This collaboration provides additional validation of our platform and its applications in drug discovery and development."

Mortazavi said the company's platform was scalable, and could be applied to all areas of biology, providing an engine for diverse drug discovery projects and enabling it to help partners in a number of ways.

"This is our third collaboration with a leading biopharmaceutical company, and we remain in business development discussions for both NDD and our functional genomics platform, GAINs."

At 0915 BST, shares in e-therapeutics were up 2.57% at 17.95p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

e-Therapeutics Market Data

Currency UK Pounds
Share Price 11.00p
Change Today -0.15p
% Change -1.35 %
52 Week High 23.10
52 Week Low 8.13
Volume 169,640
Shares Issued 584.34m
Market Cap £64.28m

e-Therapeutics Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
27.91% below the market average27.91% below the market average27.91% below the market average27.91% below the market average27.91% below the market average
48.15% above the sector average48.15% above the sector average48.15% above the sector average48.15% above the sector average48.15% above the sector average
Price Trend
59.31% below the market average59.31% below the market average59.31% below the market average59.31% below the market average59.31% below the market average
15.79% above the sector average15.79% above the sector average15.79% above the sector average15.79% above the sector average15.79% above the sector average
Income Not Available
Growth
15.52% below the market average15.52% below the market average15.52% below the market average15.52% below the market average15.52% below the market average
18.92% below the sector average18.92% below the sector average18.92% below the sector average18.92% below the sector average18.92% below the sector average

e-Therapeutics Dividends

No dividends found

Trades for 28-Mar-2024

Time Volume / Share Price
16:35 21 @ 11.00p
16:35 2 @ 11.00p
16:35 19 @ 11.00p
16:29 9 @ 10.80p
16:29 9 @ 11.00p

e-Therapeutics Key Personnel

Chair Trevor Mervyn Jones
CEO Ali Mortazavi

Top of Page